Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05669911 · ClinicalTrials.gov registry record · NA
Development of a Self-collection Device for Cervical Cancer Screening
A NA study of Human Papilloma Virus and Human Papilloma Virus Infection Type 16, sponsored by Teal Health.
- Active
- Registry status
- NA
- Development phase
- 235
- Enrollment target
- 6
- Study locations
NCT05669911: Active NA study of Human Papilloma Virus and Human Papilloma Virus Infection Type 16, sponsored by Teal Health.
NCT05669911 is a NA study of Human Papilloma Virus and Human Papilloma Virus Infection Type 16 that is active but no longer recruiting, run by Teal Health. The registered enrollment target is 235 participants, below the 8,435-participant average among 39 other Human Papilloma Virus trials with a reported enrollment target (97% lower). The trial reports 6 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05669911, a NA study of Human Papilloma Virus and Human Papilloma Virus Infection Type 16, is active but no longer recruiting, sponsored by Teal Health.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 235 participants
- Enrollment target
- 6
- Study locations
Study Summary
Evaluation of a novel self-collection device for cervical cancer screening.
Primary Outcome
Evaluate SAEs to confirm that SAEs from self-collection are equivalent to the rate of SAEs from health care provider-collection
Conditions Studied
Interventions
- DEVICE Teal Health Self-Collection Device Group
Study Locations (6)
California
- Crescendo MD - Portola Valley
Colorado
- University of Colorado Anschutz Medical Campus - Aurora
Louisiana
- Woman's Hospital - Baton Rouge
Massachusetts
- Boston Metro - Westwood
Texas
- Planned Parenthood Gulf Coast - Houston
Wisconsin
- University of Wisconsin - Madison - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 235 participants |
| Start Date | 2022-08-28 |
| Est. Completion | 2023-12-31 |
| Phase | NA |
What the registry record for NCT05669911 still lists
NCT05669911 is an interventional study that assigns participants to a tested intervention. The registered 235 participants enrollment target is mid-sized for trials with a published cap, below the 8,435-participant average among 39 other Human Papilloma Virus trials with a reported enrollment target (97% lower).
The record links to 3 conditions, with Human Papilloma Virus appearing as the primary indexed condition, and to 1 intervention - of which Teal Health Self-Collection Device Group is the first listed.
NCT05669911 lists 6 locations in 6 states (California, Colorado, Louisiana).
Frequently Asked Questions
What is clinical trial NCT05669911 about?
NCT05669911 is a clinical study titled "Development of a Self-collection Device for Cervical Cancer Screening". Evaluation of a novel self-collection device for cervical cancer screening.
What is the current status of trial NCT05669911?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 235 participants. The study started on 2022-08-28. Estimated completion is 2023-12-31.
What conditions does trial NCT05669911 study?
This clinical trial studies the following conditions: Human Papilloma Virus, Human Papilloma Virus Infection Type 16, Human Papilloma Virus Infection Type 18.
What interventions are being tested in trial NCT05669911?
The interventions under investigation include: Teal Health Self-Collection Device Group (DEVICE).
Who is sponsoring clinical trial NCT05669911?
This trial is sponsored by Teal Health, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05669911 being conducted?
This trial has 6 study locations across California, Colorado, Louisiana, Massachusetts, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Human Papilloma Virus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05669911's enrollment target sits among peer trials
235 17th of 39 higher than 23 of 39 other Human Papilloma Virus trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Human Papilloma Virus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Educate and Improve Underserved Populations' Uptake and Completion of the HPV Vaccine
RECRUITING · NA
-
PopSci CHW4CervixHealth
RECRUITING · NA
-
Advancing HPV Vaccination Among HIV Positive Adults: The CHAMPS Study
RECRUITING · NA
-
Provider Recommendation and HPV Vaccination
RECRUITING · NA
-
Impact of Standing Orders Optimization
ACTIVE NOT RECRUITING · NA
-
Impact of Financial Incentives
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01524211 · 235 participants · NA
Evaluation of Branch Endografts in the Treatment of Aortic Aneurysms
- NCT05316155 · 235 participants · Phase 1
Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer
- NCT05353569 · 235 participants · NA
Coherent Optical Detection of Middle Ear Disease
- NCT05390918 · 235 participants · NA
Targeting Adolescent Insomnia to Lessen Overall Risk of Suicidal Behavior
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI